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Protocol
AbstrACt
Introduction The sequelae of multidrug-resistant 
tuberculosis (MDR-TB) are poorly understood and 
inconsistently reported. We will aim to assess the existing 
evidence for the clinical, psychological, social and 
economic sequelae of MDR-TB and to assess the health-
related quality of life in patients with MDR-TB.
Methods and analysis We will perform a systematic 
review and meta-analysis of published studies reporting 
sequelae of MDR-TB. We will search PubMed, SCOPUS, 
ProQuest, Web of Science and PsychINFO databases up 
to 5 September 2017. MDR-TB sequelae will include 
any clinical, psychological, social and economic effects 
as well as health-related quality of life that occur after 
MDR-TB treatment or illness. Two researchers will screen 
the titles and abstracts of all citations identified in our 
search, extract data, and assess the scientific quality 
using standardised formats. Providing there is appropriate 
comparability in the studies, we will use a random-effects 
meta-analysis model to produce pooled estimates of MDR-
TB sequelae from the included studies. We will stratify the 
analyses based on treatment regimen, comorbidities (such 
as HIV status and diabetes mellitus), previous TB treatment 
history and study setting.
Ethics and dissemination As this study will be based on 
published data, ethical approval is not required. The final 
report will be disseminated through publication in a peer-
reviewed scientific journal and will also be presented at 
relevant conferences.
PrOsPErO registration number CRD42017073182.
IntrOduCtIOn 
Multidrug-resistant tuberculosis (MDR-TB) is 
a global threat that has several documented 
sequelae in affected patients.1 MDR-TB is 
caused by Mycobacterium tuberculosis and is 
defined as TB that is resistant to at least isoni-
azid and rifampicin, the two most effective 
first-line, anti-TB drugs.2 Approximately half a 
million people are estimated to have MDR-TB 
annually.3 In 2016, 490 000 new MDR-TB 
and 110 000 rifampicin-resistant tubercu-
losis (RR-TB) cases were estimated to have 
occurred.3 In the same year, 240 000 people 
were estimated to have died due to MDR-TB 
or RR-TB worldwide.3 The treatment of 
MDR-TB is more costly, toxic and has a longer 
duration than the treatment of drug-suscep-
tible TB.4 5 As a result, the drugs used to treat 
MDR-TB, as well as the disease itself, can lead 
to a range of side effects and consequences, 
ranging from mild, self-limiting to life-threat-
ening conditions.6–8 However, the burden of 
MDR-TB sequelae has not been quantified—
essential information for understanding the 
global burden of disease and associated social 
and economic costs.
Sequelae refer to conditions that are the 
consequence of a previous disease or injury.9 
Post-treatment sequelae are contextually 
defined in our study as any consequence 
of MDR-TB treatment that occurred after a 
full course of treatment or after exposure to 
TB medicine, even if the exposure was not a 
full course. Post-illness sequelae include the 
long-term and short-term consequences of 
MDR-TB.10–12 The term ‘MDR-TB sequelae’ 
here refers to both sequelae arising from 
illness and sequelae arising as side effects of 
treatment. This includes any clinical, psycho-
logical, social and economic sequelae as well 
as health-related quality of life that occurs 
after MDR-TB treatment or illness.
strengths and limitations of this study
 ► This will be the first published systematic review 
and meta-analysis that comprehensively assesses 
multidrug-resistant tuberculosis (MDR-TB) sequelae 
in people who were diagnosed with or treated for 
MDR-TB.
 ► The search will be conducted without geographical, 
language and time restrictions.
 ► The search will be performed with the help of 
a specialised librarian experienced in medical 
literature searching.
 ► The data reporting will adhere to the Preferred 
Reporting Items for Systematic reviews and Meta-
Analyses Protocols.
 ► A potential limitation of this study will be a large 
degree of heterogeneity between published studies.
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A variety of clinical sequelae occur in treated or 
untreated MDR-TB patients due to drug side effects or 
due to the disease itself. The clinical sequelae related 
to the disease comprise a range of long-lasting compli-
cations such as impaired pulmonary function, chronic 
obstructive pulmonary disease (COPD), lung scarring 
(fibrosis), bronchiectasis that leads to recurrent infec-
tions, TB (including acquired drug resistance) and heart 
failure.13 14 The common post-treatment sequelae that 
occur as a result of acute or ongoing drug side effects 
include hearing loss, visual disturbances, hepatitis, renal 
dysfunction, bone marrow suppression and peripheral 
neuropathy.15 There are also other side effects that are 
specific to the drugs used to treat MDR-TB.16 17
The economic sequelae of MDR-TB are a result of both 
direct medical costs incurred by diagnosis and treatment 
and indirect costs including productivity loss, sale of assets 
and interests on loans during treatment, due to ill health 
or long absences from the workplace.18 While there are 
also costs to the health service, we will focus only on finan-
cial sequelae imposed on an individual due to MDR-TB 
treatment or illness.
The psychological and social effects of MDR-TB are 
diverse. Depression, anxiety, substance use, stigma, 
discrimination and distress are thought to be the common 
psychological and social issues reported among patients 
with MDR-TB.12 19 In addition, like any other chronic 
illness, MDR-TB can also affect the health-related quality 
of life.20
It has been reported in previous studies that MDR-TB 
sequelae increase the risk of TB recurrence21 and death.22 
The magnitude and severity of MDR sequelae vary, and 
the risk factors for these sequelae are diverse. Some of the 
risk factors for MDR-TB sequelae are underlying comor-
bidities such as HIV infection and diabetes mellitus (DM), 
previous history of TB treatment, the pattern of drug 
resistance and the treatment regimen used.22–24
Serious MDR-TB sequelae further increase the popu-
lation impact of the disease.25 The MDR-TB surveillance 
systems in several countries have reported only MDR-TB 
cases and their treatment outcomes. However, MDR-TB 
sequelae also need to be monitored and quantified to esti-
mate the true burden of the disease, evaluate the potential 
benefit of preventive methods and measure effectiveness 
of treatment regimens. Post-MDR-TB sequelae may persist 
even after successful treatment outcomes.25 Further, a 
variety of sequelae and complications can occur in both 
treated and untreated cases of MDR-TB.26
Despite the fact that several individual studies have 
reported on the most common MDR-TB sequelae and 
their risk factors, there is no published systematic review 
and meta-analysis that shows pooled estimates of MDR-TB 
sequelae. Having a comprehensive understanding of 
MDR-TB sequelae and identifying the main risk factors 
for MDR-TB are important for clinicians, policy-makers, 
programme managers, health professionals and 
researchers in order to better understand how MDR-TB 
affects patients over the longer term. It may inform more 
effective long-term follow-up and medical care of these 
patients and prevention of the sequelae. Therefore, 
the aim of this systematic review and meta-analysis is to 
review the existing literature and quantify the burden of 
MDR-TB sequelae and to identify risk factors for these 
sequelae.
ObjECtIvEs
The objectives of our study are:
1. to review the clinical sequelae and health-related qual-
ity of life in patients with MDR-TB treatment or illness
2. to determine the prevalence of psychological and so-
cial sequelae in patients with MDR-TB
3. to measure the economic burden of MDR-TB faced by 
patients and affected families
4. to identify risk factors for MDR-TB sequelae.
MEthOds
Protocol
We have developed this systematic review and meta-anal-
ysis protocol according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses Proto-
cols (online supplementary appendix 1).27 The review 
protocol for the study has been registered in the Inter-
national Prospective Register of Systematic Reviews 
(CRD42017073182).
search strategy
We will search for studies in PubMed, SCOPUS, 
ProQuest, Web of Science and PsychINFO databases 
up to 5 September 2017, with no limitations on year or 
language of publication. We will restrict our search to 
human studies (only). We will develop search terms in 
accordance with the Medical Subject Headings (MeSH) 
thesaurus using a combination of keywords. For MDR-TB, 
we will use keywords “Tuberculosis, Multidrug-Resis-
tant”[Mesh], “drug-resistan*”, “multidrug resistan*”, 
“mdr*”, “xdr*”, “tuberculosis” and “tb”; for clinical, 
psychological, social and economic sequelae as well as 
quality of life, we will use keywords that are related to each 
term. The full electronic search strategies are included in 
the supplementary information (online supplementary 
appendix 2). We have developed our search strategy with 
the help of a medical librarian skilled in doing systematic 
reviewers. In addition, we will perform a hand search of 
the reference lists of retrieved articles and abstracts from 
the International Union Against Tuberculosis and Lung 
Disease Journal (2004–2017), the European Respiratory 
Journal, Tuberculosis and Lancet Respiratory Medicine, 
for additional papers. We will contact authors of relevant 
papers by email when additional information is required.
selection of studies
All citations identified through our search strategy will be 
imported into EndNote V.X7 (Thompson Reuters, New 
York, New York, USA). After excluding duplicated studies 
from our EndNote Library, the title and abstracts of the 
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remaining articles will be independently assessed by two 
reviewers (KAA and DS), with final inclusion of studies 
to be decided through consensus. Differences will be 
resolved by discussion with a third author (KV). If the title 
and abstract of a paper appear relevant, the full text of 
the paper will be reviewed. We will include studies based 
on the following eligibility criteria.
Participants
Studies examining clinical, psychological, social and 
economic sequelae as well as health-related quality of life 
in persons with MDR-TB treatment or illness.
Outcomes
Studies explicitly reporting on clinical, psychological, 
social and economic sequelae, as well as health-related 
quality of life
 ► Clinical sequelae: pulmonary function, COPD, bron-
chiectasis, fibrosis, aspergilloma, granuloma/calci-
fication, heart failure, hearing impairment, visual 
disturbance, liver toxicity, renal dysfunction, bone 
marrow suppression and peripheral neuropathy. It 
will also include any disability that occurred as a result 
of MDR-TB or its treatment.
 ► Health-related quality of life: physical, psychological, 
social, mental and environmental domains of quality 
of life.
 ► Social and psychological sequelae: depression, anxiety, 
psychosis, stigma, discrimination, distress and mental 
health disorders including substance abuse.
 ► Economic sequelae: cost of illness, productivity loss, 
sales of assets, interest on loans and loss of job.
Study designs
Observational studies, such as retrospective cohort, 
prospective cohort and cross-sectional studies, as well as 
interventional studies will be included.
We will exclude studies that focus only on drug-suscep-
tible TB.
data extraction
Data will be extracted from eligible studies by two inde-
pendent reviewers (KAA and DS), and information will 
be collated in a Microsoft Excel 2016 spreadsheet (Micro-
soft, Redmond, Washington, USA). The data extraction 
spreadsheet will be piloted on five different hand-
searched papers. We will collect data on the outcomes of 
our study from each individual paper.
We will record post-MDR-TB sequelae as prevalence, 
cumulative incidence, incidence density or incidence 
proportion as reported in the individual papers. We will 
also record relative risks or odds ratios to calculate rela-
tive risk compared with controls if data are available.
We will also extract the following data from each 
paper: name of first author, year of publication, country 
in which the study was conducted, study design, number 
of included study participants (that will be used as a 
denominator for all of the outcomes), participation 
rate, baseline socioeconomic indicators, demographic 
factors (including mean age in years and percentage of 
male patients), diagnostic method to ascertain MDR-TB, 
mean number of drugs to which the patient’s isolate was 
resistant, percentage of patients with HIV infection and 
percentage of patients with DM at baseline (if known). 
We will also collect data on the mean number of drugs 
provided to MDR-TB patients, the mean duration of 
MDR-TB treatment in months, treatment regimen (ie, 
standardised vs individualised and ambulatory or commu-
nity-based vs hospitalised), the percentage of patients 
who received a fluoroquinolone antibiotic (levofloxacin, 
moxifloxacin, gatifloxacin or sparfloxacin) as part of 
their treatment regimen, the percentage of patients who 
received second-line injectable drugs and the percentage 
of patients who received cycloserine.
Quality assessment
Two authors (KAA and DS) will assess the methodological 
quality of the included studies, including the risk of bias 
in the selection of the study groups (ie, people diagnosed 
with MDR-TB) and outcome ascertainment using the 
Newcastle-Ottawa Scale.28
stAtIstICAl AnAlysIs
data analysis
Data extracted from selected studies will be presented in 
evidence tables. We will undertake the descriptive statis-
tical analyses of the extracted data using STATA V.14.1. 
Because of anticipated heterogeneity, we plan to use a 
Bayesian random-effects meta-analysis model to obtain 
pooled estimates of prevalence across studies for the 
outcomes of interest. This model will assume that there is 
heterogeneity of true-effect sizes (ie, MDR-TB sequelae), 
and our goal will be to estimate the mean of this value.29 
The method will also allow direct interpretation of cred-
ible intervals of the posterior-effect estimates and inves-
tigations of sources of heterogeneity by considering 
underlying risk factors.29 30 The posterior parameters will 
be estimated using a large number of vague but proper 
prior distributions and data information using a Bayesian 
Markov Chain Monte Carlo simulation approach with 
Gibbs sampling, employed by WinBUGS V.1.4.3 software 
(Medical Research Council Biostatistics Unit, Cambridge, 
UK). After an initial burn-in and observation of conver-
gence, assessed using Brooks-Gelman criteria,31 the 
model will be run subsequently for 100 000 iterations to 
provide values for the posterior distributions. Posterior 
distributions will be summarised according to mean and 
95% credible interval limits.
Assessment of heterogeneity and reporting biases
The magnitude of variation or heterogeneity between 
studies will be quantitatively measured by index of 
heterogeneity (I2 and its CI).32 I2 values of 25%, 50% 
and 75% are assumed to represent low, medium and 
high heterogeneity, respectively. The significance of the 
heterogeneity will be determined by χ2 for Q statistics 
at a P value less than 0.05. Funnel plots will be used to 
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detect potential publication bias and small-study effects. 
A P value <0.05 will be considered as indicative of statisti-
cally significant publication bias. For outcomes with more 
than 10 individual studies, we will use the Egger method 
to assess asymmetry.
subgroup and sensitivity analysis
We will conduct a subgroup analysis to assess the effects 
of each study characteristic on the primary outcomes of 
the study. Stratified analysis will be performed by: the 
study setting (ie, high and low TB burden countries, 
based on the WHO high burden county lists for TB),33 
treatment regimens (standardised and individualised 
treatment), HIV prevalence (0 and >0%) and history 
of previous TB treatment (<75% and >75%). Sensitivity 
analyses will be also performed to verify the robust-
ness of the study conclusion and to assess the impacts 
of methodological quality, sample size and analysis 
methods on the results.
dIsCussIOn
The number of MDR-TB cases and associated post-
MDR-TB sequelae has increased in several countries 
and has posed additional challenges for national TB 
prevention and control programs.5 13 14 25 Expanding 
healthcare provided by national TB programmes to 
address the consequences or sequelae of MDR-TB 
is essential for effective TB management. Although 
previous studies have shown that in many settings the 
clinical, psychological and financial burden of MDR-TB 
is significantly higher than for person with drug-suscep-
tible TB,6–8 18 the sequelae of MDR-TB are poorly under-
stood and inconsistently reported.
This systematic review and meta-analysis will provide 
pooled estimates of MDR-TB sequelae among people who 
were diagnosed with or treated for MDR-TB. It will also 
identify the main risk factors for MDR-TB sequelae. Iden-
tifying the main risk factors for long-term and short-term 
sequelae of MDR-TB using a comprehensive systematic 
review and meta-analysis will provide empirical evidence 
necessary for clinicians, health professionals, researchers 
and decision-makers to better understand the risk factors, 
policy implications, future research needs and program-
ming priorities for the treatment, care and follow-up of 
persons with MDR-TB.
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